<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954782</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0003</org_study_id>
    <secondary_id>2019-002593-31</secondary_id>
    <nct_id>NCT03954782</nct_id>
  </id_info>
  <brief_title>Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.</brief_title>
  <acronym>EPICURE</acronym>
  <official_title>Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recognized manifestations of HHT are all due to abnormalities in vascular structure.
      Epistaxis are spontaneous, very variable, may occur as often as several times every day, and
      are recurrent in 90% of patients and associated with chronic and severe anemia in 2-10%. They
      also significantly reduce quality of life.

      Blood transfusions are sometimes required in 10-30% of patients. Previous studies showed that
      antiangiogenic treatments such as anti-VEGF treatment (bevacizumab) administered
      intravenously was efficient on epistaxis and dramatically reduced nosebleeds.

      Tyrosine kinase inhibitors are anti-angiogenic molecules which are available orally and could
      therefore overcome the difficulties encountered with bevacizumab. The investigator
      hypothesized that nintedanib, acting by indirect inhibition of the VEGF receptor should allow
      a reduction of epistaxis in HHT patient.

      Nintedanib has been used in one HHT patient following the diagnosis of Insterstitial
      Pulmonary Fibrosis (published case report in 2017, Kovacs et al) with encouraging results.

      The aim is to evaluate efficacy of nintedanib for the treatment of epistaxis in HHT patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epistaxis duration assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy or nintedanib assessed by ESS (Epistaxis Severity Score) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>This score assess the severity of epistaxis (minimum 0 corresponds to &quot;none&quot; and maximum 10 corresponds to&quot;severe&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy or nintedanib assessed by ESS questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>This score assess the severity of epistaxis (minimum 0 corresponds to &quot;none&quot; and maximum 10 corresponds to&quot;severe&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis all over the study. Assessment on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF36 (Short Form 36) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF36 questionnaire</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of red blood cell transfusions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of red blood cell transfusions</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of iron infusions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of iron infusions</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemorrhagic Hereditary Telangiectasia</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment of Nintedanib 150 mg soft capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment of placebo soft capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib 150 mg and 100 mg soft capsules</intervention_name>
    <description>Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.</description>
    <arm_group_label>Nintedanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral treatment of placebo soft capsule</intervention_name>
    <description>Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Patients who have given their free informed and signed consent

          -  Patients affiliated to a social security scheme or similar

          -  Patients monitored for clinically confirmed HHT and/or with molecular biology
             confirmation

          -  Patient with an Epistaxis Severity Score (ESS) &gt; 4

        Exclusion Criteria:

          -  Pregnant woman or woman of child bearing potential

          -  Woman who are breast feeding.

          -  Patient who is protected adults under the terms of the law (French Public Health
             Code).

          -  Participation in another interventional clinical trial which may interfere with the
             proposed trial

          -  Active infection.

          -  (AST, ALT &gt; 1,5 fold upper limit of normal (ULN) and/or Bilirubin &gt; 1,5 fold upper
             limit of normal (ULN).

          -  Severe renal impairment

          -  Presence of non-treated pulmonary arteriovenous malformations accessible to a
             treatment on CT scan within 5 years.

          -  Patients with hemoptysis or hematuria within 12 weeks prior to inclusion.

          -  Patients with active gastro-intestinal (GI) bleeding or GI ulcers.

          -  Presence of cerebral arteriovenous malformation.

          -  Patients who require full-dose therapeutic anticoagulation (e.g. vitamin K antagonist
             or heparin, dabigatran) or high dose antiplatelet therapy, , patients under
             anticoagulation with rivaroxaban, apixaban and epixaban.

          -  Patients with P-glycoprotein (P-gp) substrates/inducers/inhibitors (e.g.:
             ketoconazole, erythromycin, cyclosporine, rifampicin, carbamazepine, phenytoin, and
             St. John's Wort).

          -  Patients with known coronary artery disease or recent history of myocardial infarction
             (within 1 year).

          -  Known inherited predisposition to thrombosis or thrombotic events within 12 months
             prior to inclusion.

          -  Patients with QTc prolongation

          -  Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients.

          -  Patient who incompletely filled in epistaxis grids within 8 weeks prior to inclusion.

          -  Patient who have received intravenous bevacizumab within 6 months prior to inclusion.

          -  Patient who had surgery (including ENT (Ear, Nose and Throat Specialist) surgery)
             within 12 weeks prior to inclusion.

          -  Unhealed wound.

          -  Planned major surgery within the next 3 months, including liver transplantation, major
             abdominal or intestinal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie DUPUIS-GIROD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie DUPUIS-GIROD, MD</last_name>
    <phone>4 27 85 65 25</phone>
    <phone_ext>+33</phone_ext>
    <email>sophie.dupuis-girod@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>C LAVIGNE</last_name>
      <email>chlavigne@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>C LAVIGNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry CHINET</last_name>
      <email>thierry.chinet@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry CHINET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant-Centre de Référence pour la maladie de Rendu-Osler</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie DUPUIS-GIROD</last_name>
      <email>sophie.dupuis-girod@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent GROBOST</last_name>
      <email>vincent.grobost@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vincent GROBOST</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hélène MAILLARD</last_name>
      <email>helene.maillard@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène MAILLARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille-Hôpital la conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier-Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie RIVIERE</last_name>
      <email>s-riviere@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie RIVIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Antoine PARROT</last_name>
      <email>antoine-parrot@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine PARROT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital J.Bernard</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Brigitte GILBERT-DUSSARDIER</last_name>
      <email>brigitte.gilbert-dussardier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte GILBERT-DUSSARDIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes-Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemorrhagic Hereditary Telangiectasia (HHT)</keyword>
  <keyword>antiangiogenic therapy</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Nintedanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

